JP2012515164A - 角膜障害を処置するための治療組成物 - Google Patents

角膜障害を処置するための治療組成物 Download PDF

Info

Publication number
JP2012515164A
JP2012515164A JP2011545490A JP2011545490A JP2012515164A JP 2012515164 A JP2012515164 A JP 2012515164A JP 2011545490 A JP2011545490 A JP 2011545490A JP 2011545490 A JP2011545490 A JP 2011545490A JP 2012515164 A JP2012515164 A JP 2012515164A
Authority
JP
Japan
Prior art keywords
corneal
subject
nerve
composition
cornea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011545490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515164A5 (cg-RX-API-DMAC7.html
Inventor
レーザ ダナ
ムハンマッド ダストジェルディ
スニル シャウハン
Original Assignee
ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド filed Critical ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド
Publication of JP2012515164A publication Critical patent/JP2012515164A/ja
Publication of JP2012515164A5 publication Critical patent/JP2012515164A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011545490A 2009-01-09 2010-01-11 角膜障害を処置するための治療組成物 Pending JP2012515164A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14356109P 2009-01-09 2009-01-09
US61/143,561 2009-01-09
PCT/US2010/020646 WO2010081091A2 (en) 2009-01-09 2010-01-11 Therapeutic compositions for treatment of corneal disorders

Publications (2)

Publication Number Publication Date
JP2012515164A true JP2012515164A (ja) 2012-07-05
JP2012515164A5 JP2012515164A5 (cg-RX-API-DMAC7.html) 2013-07-25

Family

ID=42144303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011545490A Pending JP2012515164A (ja) 2009-01-09 2010-01-11 角膜障害を処置するための治療組成物

Country Status (6)

Country Link
US (1) US10117906B2 (cg-RX-API-DMAC7.html)
EP (1) EP2385839B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012515164A (cg-RX-API-DMAC7.html)
AU (1) AU2010203425B2 (cg-RX-API-DMAC7.html)
CA (1) CA2749537C (cg-RX-API-DMAC7.html)
WO (1) WO2010081091A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015030078A1 (ja) * 2013-08-28 2015-03-05 千寿製薬株式会社 角膜上皮障害治療剤
JP2016521252A (ja) * 2013-03-13 2016-07-21 イレブン・バイオセラピユーテイクス・インコーポレイテツド 眼送達のためのキメラサイトカイン製剤

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230776T1 (hr) * 2010-07-29 2023-10-27 Buzzard Pharmaceuticals AB Himerni antagonisti receptora il-1 tipa i
WO2012103240A2 (en) * 2011-01-25 2012-08-02 Eleven Biotherapeutics, Inc. Receptor binding agents
WO2013126599A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Meibomian gland dysfunction
WO2013126602A1 (en) 2012-02-21 2013-08-29 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
WO2014036445A2 (en) * 2012-08-31 2014-03-06 Johnson Michael R Novel mucolytic agents
SG11201601291QA (en) 2013-08-23 2016-03-30 Parion Sciences Inc Dithiol mucolytic agents
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
BR112017016067A2 (pt) 2015-01-30 2018-04-03 Parion Sciences Inc agentes mucolíticos de monotiol
JP2018520986A (ja) 2015-04-30 2018-08-02 パリオン・サイエンシィズ・インコーポレーテッド ジチオール粘液溶解剤の新規なプロドラッグ
US20180312838A1 (en) * 2015-10-21 2018-11-01 The Regents Of The University Of California Modulation of microrna 184 to treat pathological lymphangiogenesis
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
WO2020218488A1 (ja) * 2019-04-26 2020-10-29 千寿製薬株式会社 眼疾患マーカー
CN113350326B (zh) * 2021-07-28 2023-03-17 爱尔眼科医院集团股份有限公司 化合物lm22b-10在制备角膜上皮及神经损伤治疗药物中的应用
KR102883890B1 (ko) * 2021-11-30 2025-11-07 한림대학교 산학협력단 miR-30c-1 발현 수준을 증가시키기 위한 제제를 사용하는 각막 내피 세포 배양 방법 및 각막 내피 세포 질환 치료용 조성물
CN118304388B (zh) * 2024-04-03 2025-02-11 南通大学 Tak1在制备治疗周围神经损伤药物中的应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015491A (ja) * 1997-02-06 2005-01-20 Inspire Pharmaceuticals Inc プリン受容体アゴニストによるドライアイ疾患の治療のための医薬組成物及び滅菌調製物
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
JP2007526292A (ja) * 2004-03-02 2007-09-13 インスティテュート オブ オフタルモロジー 目の表面及びその他の障害のための調剤薬及び治療方法
WO2007120828A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
JP2008534680A (ja) * 2005-04-04 2008-08-28 アドバンスト メディカル オプティクス, インコーポレーテッド ドライアイ緩和用のヒアルロン酸ナトリウムを含有する安定な眼科用水中油型エマルジョン
WO2008118930A1 (en) * 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0610336B1 (en) 1991-10-31 2002-03-27 The Victoria University Of Manchester Treatment of neurological conditions by an interleukin-1 inhibiting compound
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
WO1998022130A1 (en) * 1996-11-19 1998-05-28 The Schepens Eye Research Institute, Inc. Local use of il-1ra in corneal transplant rejection or disorders of the eye
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
JP3363832B2 (ja) 1999-05-13 2003-01-08 アルプス電気株式会社 薄膜構造体およびその製造方法
US20030104041A1 (en) 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
EP1252895A4 (en) 2000-01-31 2003-04-16 Santen Pharmaceutical Co Ltd REMEDIES FOR OPHTHALMIC DISORDERS
WO2001057082A2 (en) 2000-02-03 2001-08-09 Regeneration Technologies, Inc. Extraction of growth factors from tissue
US20010047204A1 (en) * 2000-03-20 2001-11-29 Medennium, Inc. Method for determination of a properly sized posterior chamber phakic refractive lens
US20020131954A1 (en) 2000-05-02 2002-09-19 Tobinick Edward L. Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US20050143333A1 (en) 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
WO2003022213A2 (en) 2001-09-06 2003-03-20 Board Of Regents, The University Of Texas System Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US6890654B2 (en) 2002-04-18 2005-05-10 Northwestern University Encapsulation of nanotubes via self-assembled nanostructures
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20050033694A1 (en) * 2003-06-03 2005-02-10 United States Postal Service. System and method for fleet card management
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050023872A1 (en) * 2003-07-28 2005-02-03 Hetzel Thomas R. Modular seat cushion with interlocking human support and base portions and method of creating and using a seat cushion
KR100543466B1 (ko) * 2003-11-13 2006-01-20 삼성전자주식회사 영상 보간 장치 및 방법
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
CA2588449A1 (en) * 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
JP4815808B2 (ja) 2005-01-24 2011-11-16 三菱電機株式会社 ロータリ圧縮機
CN102293774A (zh) 2005-03-31 2011-12-28 旭硝子株式会社 前列腺素F2α衍生物的应用
EP1870099A4 (en) 2005-04-13 2008-07-16 Ube Industries PROTECTION AGAINST RETINAL NERVOUS CELLS WITH INDAZOLE DERIVATIVE AS ACTIVE SUBSTANCE
US7670849B2 (en) 2005-04-29 2010-03-02 Henkin Robert I Method for diagnosing insulin resistance from nasal secretions
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
CN101489569A (zh) 2006-06-12 2009-07-22 席拉坎有限责任公司 眼表面疾病的局部治疗
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
EP2187900B1 (en) 2007-08-16 2016-11-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CA2711696C (en) * 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
US9011861B2 (en) * 2010-02-25 2015-04-21 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015491A (ja) * 1997-02-06 2005-01-20 Inspire Pharmaceuticals Inc プリン受容体アゴニストによるドライアイ疾患の治療のための医薬組成物及び滅菌調製物
JP2007526292A (ja) * 2004-03-02 2007-09-13 インスティテュート オブ オフタルモロジー 目の表面及びその他の障害のための調剤薬及び治療方法
JP2008534680A (ja) * 2005-04-04 2008-08-28 アドバンスト メディカル オプティクス, インコーポレーテッド ドライアイ緩和用のヒアルロン酸ナトリウムを含有する安定な眼科用水中油型エマルジョン
WO2007027761A2 (en) * 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
WO2007120828A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
WO2008118930A1 (en) * 2007-03-26 2008-10-02 Zymogenetics, Inc. Soluble il-17ra/rc fusion proteins and related methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5012005748; BISWAS PARTHA SARATHI: 'COUNTERACTING CORNEAL IMMUNOINFLAMMATORY LESION WITH INTERLEUKIN-1 RECEPTOR ANTAGONIST PROTEIN' JOURNAL OF LEUKOCYTE BIOLOGY V76 N4, 200410, P868-875 *
JPN6014007336; Biochem.Biophys.Res.Commun. 234, 1997, p.211-215 *
JPN6014007339; J.Immunol. 169, 2002, p.5897-5903 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016521252A (ja) * 2013-03-13 2016-07-21 イレブン・バイオセラピユーテイクス・インコーポレイテツド 眼送達のためのキメラサイトカイン製剤
WO2015030078A1 (ja) * 2013-08-28 2015-03-05 千寿製薬株式会社 角膜上皮障害治療剤
US9562231B2 (en) 2013-08-28 2017-02-07 Senju Pharmaceutical Co., Ltd. Therapeutic agent for corneal epithelial disorder
JPWO2015030078A1 (ja) * 2013-08-28 2017-03-02 千寿製薬株式会社 角膜上皮障害治療剤

Also Published As

Publication number Publication date
WO2010081091A3 (en) 2010-11-18
US20100183587A1 (en) 2010-07-22
AU2010203425A1 (en) 2011-07-28
CA2749537A1 (en) 2010-07-15
CA2749537C (en) 2018-11-20
WO2010081091A2 (en) 2010-07-15
US10117906B2 (en) 2018-11-06
AU2010203425B2 (en) 2015-04-09
EP2385839B1 (en) 2014-11-26
EP2385839A2 (en) 2011-11-16

Similar Documents

Publication Publication Date Title
AU2010203425B2 (en) Therapeutic compositions for treatment of corneal disorders
JP5886523B2 (ja) 眼の炎症性障害を処置するための治療組成物
US20250195608A1 (en) Therapeutic Compositions for the Treatment of Dry Eye Disease
Cvenkel et al. Current medical therapy and future trends in the management of glaucoma treatment
US10105441B2 (en) Method for inhibiting or reducing dry eye disease by IL-1Ra
Shah et al. Translational Preclinical Pharmacologic Disease Models for Ophthalmic Drug Development: Mihir et al.
JP2011516400A5 (cg-RX-API-DMAC7.html)
Chucair-Elliott et al. IL-6 contributes to corneal nerve degeneration after herpes simplex virus type I infection
Gagliano et al. Intravitreal steroids for the prevention of PVR after surgery for retinal detachment
US20120014970A1 (en) Therapeutic Compositions for Treatment of Corneal Disorders
JP6440107B2 (ja) 細胞シートの製造方法、組成物、細胞培養補助剤、及び細胞培養方法
CA2640986C (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
AU2014227534B2 (en) Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
CN114206849A (zh) 用于治疗非感染性眼部免疫炎性病症的治疗方法
Augustine The role of Interleukin-33 in Retinal degenerative diseases

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141120